Novel Mitochondria-Targeting Peptide in Heart Failure Treatment A Randomized, Placebo-Controlled Trial of Elamipretide
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment A Randomized, Placebo-Controlled Trial of Elamipretide
复制标题
DOI：
10.1161/circheartfailure.117.004389
复制
发表时间：
2017-12-01
影响因子：
9.7
通讯作者：
Sabbah, Hani N.
中科院分区：
文献类型：
--
作者：
Daubert, Melissa A.;Yow, Eric;Sabbah, Hani N.
背景：心力衰竭中的线粒体功能障碍和能量消耗是心力衰竭管理的创新治疗靶点。埃拉米普瑞肽是一种新的四肽，可增加线粒体能量;然而，其安全性、耐受性和对心脏结构和功能的治疗效果尚未在射血分数降低的心力衰竭中进行研究。
BACKGROUND: Mitochondrial dysfunction and energy depletion in the failing heart are innovative therapeutic targets in heart failure management. Elamipretide is a novel tetrapeptide that increases mitochondrial energy; however, its safety, tolerability, and therapeutic effect on cardiac structure and function have not been studied in heart failure with reduced ejection fraction.METHODS AND RESULTS: In this double-blind, placebo-controlled, ascending-dose trial, patients with heart failure with reduced ejection fraction (ejection fraction,